Digital therapeutics agency, Sidekick Well being has joined forces with pharma large Pfizer to launch an built-in digital therapeutics answer for Atopic Dermatitis (AD).
The answer will likely be rolled-out within the UK first, adopted by Belgium, Norway, the Netherlands, Sweden, France, Eire, and Japan later this yr.
This marks the subsequent section of a rising collaboration between Sidekick and Pfizer to develop digital affected person assist programmes globally, together with growth into 24 markets by 2024.
WHY IT MATTERS
AD is an inflammatory, pruritic, persistent, or chronically relapsing pores and skin illness that impacts as much as 14% of adults worldwide. Individuals dwelling with average to extreme AD usually undergo from fixed and relentless itching, resulting in sleep deprivation, elevated stress and anxiousness that impacts the standard of their lives.
Nevertheless, one of many challenges of successfully treating AD is that sufferers’ adherence to remedy tends to be low. Sidekick’s digital therapeutics platform goals to handle this utilizing gamification rules and behavioural economics to ship remedy by care pathways that assist encourage lasting behavioural change. This positively impacts well being outcomes by addressing the identical endpoints as conventional remedies.
Sidekick just lately accomplished an independently funded feasibility examine for AD, displaying a discount in pores and skin lesion severity and extension by greater than 40%, as evaluated by dermatologists, and near 50% discount within the general severity of signs.
Individuals who participated within the examine additionally reported a big enchancment in health-related high quality of life and elevated adherence to remedies and preventive measures.
THE LARGER CONTEXT
Earlier this month, Sidekick introduced the closing of a $55 million (€52M) Collection B spherical which brings its complete funding in lower than two years to $75 million (€70.8M).
In addition to partnering with Pfizer, the agency has beforehand labored with international pharma agency Bayer, to develop built-in mixture therapeutics.
ON THE RECORD
Dr Tryggvi Thorgeirsson, CEO and cofounder, Sidekick, stated: “We’re extraordinarily excited to be getting into the subsequent section in our ongoing relationship with Pfizer. At Sidekick, it’s all the time been our ambition to assist as many individuals as potential to make long-lasting enhancements to their illness administration, with the purpose of enhancing folks’s well being outcomes and high quality of life. Our work with Pfizer escalates our mission to deliver digital therapeutics into the houses of individuals world wide.”
Ana Paula Carvalho, regional president, worldwide developed markets, irritation and immunology, Pfizer, stated: “Autoimmune and persistent inflammatory ailments resembling atopic dermatitis will be debilitating, disfiguring, and distressing, dramatically affecting what folks dwelling with the illness can do.
“At Pfizer, we acknowledge affected person care goes past medical advances and we’re proud to be working with Sidekick to place their expertise within the fingers of people that want it most. A holistic strategy to treating the person, not simply the illness, is crucial so as to advance the usual of look after sufferers and to empower them to reside their greatest lives.”